iRhythm to Acquire VitalConnect for $287.5M, Expanding Remote Cardiac Care
IRTC sits 29% above its 52-week low of $100.846.
Summary
iRhythm is acquiring VitalConnect for $287.5 million in cash and stock, adding FDA-cleared wearable biosensor tech to its cardiac monitoring platform. The deal follows yesterday's strong Q2 report where revenue beat estimates and the company raised full-year guidance. Management expects the acquisition to be accretive to revenue growth in 2027 while maintaining its 15% adjusted EBITDA margin target. Shares rose 3.68% on the news, reflecting positive initial reaction. The integration of VitalConnect's multi-vitals tracking could strengthen iRhythm's competitive position in ambulatory monitoring.
At the time of this announcement, IRTC was trading at $130.08 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.3B. The 52-week trading range was $100.85 to $212.00. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Benzinga.